Shandong Keyuan Pharmaceutical Co (SZSE:301281) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shandong Keyuan Pharmaceutical Co EBITDA Margin % Related Terms
Shandong Keyuan Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Keyuan Pharmaceutical Co EBITDA Margin % Chart
SZSE:301281 vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Shandong Keyuan Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Keyuan Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shandong Keyuan Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shandong Keyuan Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Keyuan Pharmaceutical Co (SZSE:301281) has a EBITDA Margin % of 20.30% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shandong Keyuan Pharmaceutical Co and its competitors. This is 22% below median its historical median of 25.98. Over the past decade, Shandong Keyuan Pharmaceutical Co's EBITDA Margin % has ranged from 5.78 to 33.57. According to the industry distribution chart, Shandong Keyuan Pharmaceutical Co ranks #633 out of 961 companies in the Drug Manufacturers industry, placing it in the top 65.9%.
Is Shandong Keyuan Pharmaceutical Co's EBITDA Margin % too high?
Shandong Keyuan Pharmaceutical Co's current EBITDA Margin % of 20.30% is 22% below median its 10-year median of 25.98. Over the past 10 years, this metric has ranged from a low of 5.78 to a high of 33.57. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Shandong Keyuan Pharmaceutical Co's value of 20.30% is 62.5% above this industry median. Based on the distribution chart, Shandong Keyuan Pharmaceutical Co ranks #633 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shandong Keyuan Pharmaceutical Co has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Keyuan Pharmaceutical Co's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Shandong Keyuan Pharmaceutical Co ranks #633 out of 961 companies for EBITDA Margin %. This places Shandong Keyuan Pharmaceutical Co in the lower half of its industry. The industry median EBITDA Margin % is 12.49. Shandong Keyuan Pharmaceutical Co's value of 20.30% is 62.5% above this benchmark. Historically, Shandong Keyuan Pharmaceutical Co's own EBITDA Margin % has ranged from 5.78 to 33.57 over the past decade. While the company's 10-year median is 25.98 vs. the industry median of 12.49, Shandong Keyuan Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Keyuan Pharmaceutical Co's current EBITDA Margin % of 20.30% is 62.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shandong Keyuan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Keyuan Pharmaceutical Co's current EBITDA Margin % is 20.30%, which is 22% below median its own 10-year median of 25.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Keyuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Keyuan Pharmaceutical Co (SZSE:301281) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥30.41, compared to a current price of ¥50.42 — trading 65.8% above its estimated fair value. The current EBITDA Margin % is 20.30%, which is 22% below median its 10-year median of 25.98 and 62.5% above the Drug Manufacturers industry median of 12.49. Shandong Keyuan Pharmaceutical Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shandong Keyuan Pharmaceutical Co (SZSE:301281), the current EBITDA Margin % is 20.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Keyuan Pharmaceutical Co (SZSE:301281) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Keyuan Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥50.42 is trading 65.8% above its estimated GF Value™ of ¥30.41.
GuruFocus considers Shandong Keyuan Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SZSE:301281:
EBITDA Margin %: 20.30% (22% below median its 10-year median of 25.98)
GF Value™: ¥30.41 vs. price of ¥50.42 (65.8% above fair value)
Industry Position: 62.5% above the Drug Manufacturers median (#633 of 961)
No single metric tells the full story. See the SZSE:301281 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Keyuan Pharmaceutical Co Business Description
Shandong Keyuan Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of chemical raw materials and their preparations.
67GF Score
Get the complete analysis for SZSE:301281
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301281 has been successfully added to your 
